Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025
Rhea-AI Summary
Day One Biopharmaceuticals (Nasdaq: DAWN) will report its third quarter 2025 financial results on Tuesday, November 4, 2025.
The company will host a live conference call and webcast on Nov. 4, 2025 at 4:30 p.m. ET to discuss results and corporate progress. Live audio will be available in the Events section of Day One's Media & Investors page, and an archived replay will be accessible for 30 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, DAWN gained 1.35%, reflecting a mild positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $11M to the company's valuation, bringing the market cap to $796M at that time.
Data tracked by StockTitan Argus on the day of publication.
BRISBANE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, November 4, 2025 at 4:30 p.m. ET to report financial results and discuss corporate progress for the third quarter 2025.
Live audio of the webcast will be accessible in the Events section of Day One’s Media & Investors page. An archived version of the webcast will be available for replay in the Events section for 30 days following the event.
About Day One Biopharmaceuticals
Day One Biopharmaceuticals believes when it comes to pediatric cancer, we can do better. The Company was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. Inspired by “The Day One Talk” that physicians have with patients and their families about an initial cancer diagnosis and treatment plan, Day One aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer – regardless of age – starting from day one.
Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important targeted cancer treatments. The Company’s pipeline includes tovorafenib (OJEMDA™) and DAY301.
Day One is based in Brisbane, California. For more information, please visit www.dayonebio.com or find the Company on LinkedIn or X.
Day One uses its Investor Relations website (ir.dayonebio.com), its X handle (x.com/DayOneBio), and LinkedIn Home Page (linkedin.com/company/dayonebio) as a means of disseminating or providing notification of, among other things, news or announcements regarding its business or financial performance, investor events, press releases, and earnings releases, and as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
DAY ONE MEDIA
Laura Cooper, Head of Communications
media@dayonebio.com
DAY ONE INVESTORS
LifeSci Advisors, PJ Kelleher
pkelleher@lifesciadvisors.com
FAQ
When will Day One (DAWN) report Q3 2025 results?
What time is the Day One (DAWN) Q3 2025 earnings call and webcast?
Where can investors access Day One (DAWN) live audio for the Nov. 4, 2025 webcast?
Will the Day One (DAWN) Q3 2025 webcast be available after the live event?
Is registration required to join Day One (DAWN) Nov. 4, 2025 webcast?
What will Day One (DAWN) discuss on the Nov. 4, 2025 call?
